guest ::
| Home > Publications database > Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study. > print |
| Home > Publications database > Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study. > print |
| 001 | 299546 | ||
| 005 | 20250530151900.0 | ||
| 024 | 7 | _ | |a 10.1016/j.jvir.2025.02.028 |2 doi |
| 024 | 7 | _ | |a pmid:40043833 |2 pmid |
| 024 | 7 | _ | |a 1051-0443 |2 ISSN |
| 024 | 7 | _ | |a 1535-7732 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-00490 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Tefera, Jonathan |b 0 |
| 245 | _ | _ | |a Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1748610888_4403 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Volume 36, Issue 6, June 2025, Pages 1042-1050.e2 |
| 520 | _ | _ | |a To evaluate the effectiveness of PVE and HVE compared to PVE in cirrhotic and non-cirrhotic swine.Sixteen Yorkshire pigs were included in this study. In the cirrhotic group (n = 8) and non-cirrhotic group (n = 8), subjects underwent embolization according to established protocols. CT scans were acquired before and at two- and four-week intervals following the embolization. Liver volumes were segmented in the portal venous phase. Student's t-test with a significance level at p<0.05 was used.Across all swine, the FLR was significantly larger after PVE + HVE to PVE at two weeks (24.12% [95% CI: 15.36%, 32.88%] vs. 12.75% [95% CI: 7.43%, 18.07%], p = 0.021) and four weeks (23.23% [95% CI: 15.79%, 33.47%] vs. 15.08% [95% CI: 9.98%, 20.87%], p = 0.043) post-embolization. In the cirrhotic group, the FLR increase was greater following PVE + HVE compared to PVE at two weeks (20.85% [95% CI: 14.40%, 27.30%] vs. 8.66% [95% CI: 6.47%, 10.86%], p = 0.0089) and four weeks (19.27% [95% CI: 17.87%, 20.67%] vs. 13.33% [95% CI: 9.23%, 13.33%], p = 0.0003) post-embolization.PVE + HVE resulted in greater FLR hypertrophy than PVE alone indicating that cirrhotic livers may benefit from the addition of HVE. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Kuhn, Tom N |0 P:(DE-He78)19efdf048b5b493cad9ee8d86d3ae6bf |b 1 |u dkfz |
| 700 | 1 | _ | |a Matuschewski, Nickolai J |b 2 |
| 700 | 1 | _ | |a Meister, Ellen |b 3 |
| 700 | 1 | _ | |a Nguyenová, Jana |b 4 |
| 700 | 1 | _ | |a Kao, Tabea |b 5 |
| 700 | 1 | _ | |a Mutonga, Martin |b 6 |
| 700 | 1 | _ | |a Bitar, Ryan |b 7 |
| 700 | 1 | _ | |a Kahl, Vinzent |b 8 |
| 700 | 1 | _ | |a Zhang, Xuchen |b 9 |
| 700 | 1 | _ | |a Shewarega, Annabella |b 10 |
| 700 | 1 | _ | |a Chapiro, Julius |b 11 |
| 700 | 1 | _ | |a Madoff, David C |b 12 |
| 773 | _ | _ | |a 10.1016/j.jvir.2025.02.028 |g p. S1051044325002209 |0 PERI:(DE-600)2041331-2 |n 6 |p 1042-1050.e2 |t Journal of vascular and interventional radiology |v 36 |y 2025 |x 1051-0443 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:299546 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)19efdf048b5b493cad9ee8d86d3ae6bf |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2025-01-01 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J VASC INTERV RADIOL : 2022 |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-01 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-01 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2025-01-01 |
| 920 | 1 | _ | |0 I:(DE-He78)D170-20160331 |k D170 |l KKE Neuroimmunologie und Hirntumorimmunologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D170-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|